Login / Signup

Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.

Harry YoonLilit KarapetyanAnita ChoudharyRamla KosoziGurvinder Singh BaliAli H ZaidiAjlan AtasoyArlene A ForastiereMichael K Gibson
Published in: The oncologist (2018)
Irinotecan and panitumumab as second-line treatment for advanced EAC are not active.
Keyphrases
  • phase ii study
  • locally advanced
  • wild type
  • metastatic colorectal cancer
  • open label
  • squamous cell carcinoma
  • randomized controlled trial
  • radiation therapy
  • clinical trial
  • combination therapy